This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEE2B11L_M.jpg
Investing.com — Biogen (NASDAQ:BIIB) shares were trading weaker in Tuesday’s premarket trading as the company’s study testing a treatment for a rare eye disease failed to meet its target.
The eye disease, known as choroideremia, is a rare inherited retinal disease that results in progressive vision loss, ultimately leading to blindness.
Biogen tested its timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy, for the potential treatment of choroideremia.
The phase-3 study, STAR, evaluated the safety and efficacy of a single subretinal injection of investigational timrepigene emparvovec.
The disappointing findings come as the biotech firm’s decision to price its recently-approved treatment for Alzheimer’s at $56,000 faces stiff resistance.
